MISSISSAUGA, Ontario, Oct. 4, 2018 /CNW/ -- Abbott (NYSE: ABT) announced today the company has received the Health Canada license of its FreeStyle LibreLink mobile app for use with compatible iOS ...
ABBOTT PARK, Ill. & SAN DIEGO--(BUSINESS WIRE)--Abbott (NYSE: ABT), the global health care company, and Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology ...
- FreeStyle Libre 2 system continuously measures glucose data every minute with customizable, optional real-time alarms 1 to alert users when their glucose is high or low without scanning - Now for ...
MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...
Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...
Abbott, a global healthcare leader, announced that the US Food and Drug Administration (FDA) has cleared the FreeStyle Libre 2 iOS application for use with compatible iPhones, providing a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback